GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (NAS:MCRB) » Definitions » Volatility

Seres Therapeutics (Seres Therapeutics) Volatility : 72.27% (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-04-29), Seres Therapeutics's Volatility is 72.27%.


Competitive Comparison of Seres Therapeutics's Volatility

For the Biotechnology subindustry, Seres Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seres Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Volatility falls into.



Seres Therapeutics  (NAS:MCRB) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seres Therapeutics  (NAS:MCRB) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Seres Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Seres Therapeutics (Seres Therapeutics) Business Description

Traded in Other Exchanges
Address
200 Sidney Street, 4th Floor, Cambridge, MA, USA, 02139
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Executives
Paula Cloghessy officer: See Remarks C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Matthew R. Henn officer: Chief Scientific Officer C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Eric D. Shaff officer: CFO and EVP C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Thomas Desrosier officer: See Remarks 65 HAYDEN AVENUE, LEXINGTON MA 02421
Moltke Lisa Von officer: See Remarks C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Teresa L. Young officer: See Remarks C/O SERES THERAPEUTICS, INC., SUITE 1750, HOUSTON TX 77098
David S. Ege officer: See Remarks C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Claire Fraser director C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv-rx, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142